Callahan R, et al. - Researchers explored the use of imatinib mesylate with or without bevacizumab targeting neoproliferative myofibroblast-like cells with tyrosine kinase receptor expression, as adjuncts to modern interventional therapies for the treatment of multivessel intraluminal pulmonary vein stenosis (PVS) in patients with ≥2 affected pulmonary veins after surgical or catheter-based relief of obstruction. Findings unveiled that the survival to 72 weeks was 77% in a referral cohort undergoing multimodal treatment, with the inclusion of antiproliferative tyrosine kinase blockade. Minimal toxicity was reported specific to tyrosine kinase blockade.